Kineta is led by a team with diverse talents who are recognized for their expertise in drug development and their success in bringing novel new therapies to market.
Shawn Iadonato, Ph.D.
Chief Executive Officer
Dr. Shawn Iadonato serves as Kineta’s Chief Executive Officer. Dr. Iadonato is a co-founder of Kineta and previously served as Chief Scientific Officer. Under his leadership as CSO, the Kineta pipeline expanded to include the AViiD™ Screening Platform and five novel drug and vaccine programs with a focus on autoimmune diseases, antivirals and chronic pain.
Prior to founding Kineta, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. At Illumigen Biosciences, he pioneered their patented drug discovery platform which relied upon recruitment and screening of healthy populations and elucidation of their shared "wellness" genes. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen's anti-hepatitis C drug, which ultimately led to the sale of the company in December, 2007 to Cubist Pharmaceuticals (now part of Merck & Co.). Before Illumigen, Dr. Iadonato managed the Human Genome Center at the University of Washington. He is co-inventor on more than 35 U.S. patents or patent applications. He is Principal Investigator or co-Investigator on numerous ongoing government grants and contracts. Dr. Iadonato received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.
President and Chief Operating Officer
Rob Hedequist serves as Kineta’s President and Chief Operating Officer. Mr. Hedequist previously held the roles of Chief Development Officer at KPI Therapeutics (a Kineta subsidiary) and Senior Vice President of Corporate Development at Kineta. Mr. Hedequist brings over 25 years of product launch and biopharmaceutical industry experience to Kineta. He has held numerous leadership roles within the commercial sales and marketing organizations of Fortune 100 pharmaceutical and biotechnology companies.
Prior to joining Kineta in 2013, he was responsible for managed care and Medicaid account management at Amgen. Before Amgen, he was a National Director for Schering-Plough and responsible for developing and implementing strategy across 16 national regions. Mr. Hedequist started his pharmaceutical career at Pfizer where he had increasing levels of responsibility culminating in Managed Market Manager where he coordinated product sales over $300 million per year. Over his career he has successfully launched over 10 new pharmaceutical products and 2 biological products. Prior to his career in the pharmaceutical industry, Mr. Hedequist had a stellar career in the United States Marine Corps rising from platoon commander to Major and Commanding Officer Fleet Anti-Terrorism Security Company Pacific and is a Desert Shield veteran. A former collegiate athlete, he was a member of the 1979 PAC10 Championship football team and graduated from the University of Southern California with a Bachelor of Science degree in Public Affairs.
Kristin Bedard, Ph.D.
Vice President Research & Development and Head of Virology
Dr. Kristin Bedard is a founding scientist at Kineta and heads discovery and research programs. This encompasses Kineta’s diverse pipeline of therapeutic and vaccine adjuvant candidates. She leads a multi-functional scientific team responsible for the selection and advancement of drug candidates focused on immunology and infectious disease. Under her direction, Kineta established the AViiD™ platform for identifying novel innate immune modulators including broad spectrum antivirals and vaccine adjuvants. Additionally, her team has progressed the direct-acting antiviral lead, LHF-535, into formal preclinical development for the arenavirus, Lassa Fever.
Dr. Bedard received her undergraduate degrees in Microbiology and Biochemistry at Pennsylvania State University and earned a PhD degree in Molecular Virology from University of California, Irvine where she studied the host cell- virus interactions of RNA viruses. She completed a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center studying viral induced cancers. Dr. Bedard’s work has led to three highly regarded NIH research grants and four NIH contracts for therapeutics and vaccine adjuvants. She is the co-inventor on fifteen filed U.S. patent applications for novel classes of antivirals, adjuvants, immune agonists and corresponding methods of identification. Her focus on host driven therapies is instrumental in shifting the paradigm of adjuvant and antiviral drug development strategies.
Senior Vice President Business Development and Corporate Communications
Jacques Bouchy heads business development and is responsible for strategic partnership and licensing initiatives at Kineta. Additionally, he is responsible for all corporate communications. Mr. Bouchy brings over twenty years of business development, sales and marketing experience in the pharmaceutical industry.
Prior to joining Kineta in 2014, Mr. Bouchy held numerous roles within the commercial organizations of Fortune 500 pharmaceutical companies. Most recently, he led payer strategy, pricing and contracting development and marketing of several mid to late stage assets at GSK. Before GSK, Mr. Bouchy led business development for Microvu, a medical claims overpayment recovery company. He started his career at Schering-Plough where he held roles of increasing responsibility in the sales and managed markets organizations. As a Managed Markets Director, he led a team that was accountable for annual product sales of ~$300M. Mr. Bouchy has successfully launched twelve new pharmaceutical products throughout his career. He served on the board of the American Lung Association’s Washington Asthma Initiative from 2003-2007. Mr. Bouchy earned a B.S. in Marketing from the University of Colorado.
P. Campion Fellin, MSE
Senior Vice President Operations
Camp Fellin heads Operations and provides leadership and guidance over all grant and contract award implementation, IT, accounting, and facilities management at Kineta. Mr. Fellin brings over 25 years of commercial operations and program management experience to Kineta and manages all of Kineta’s administrative and facilities operations.
Prior to joining Kineta, Mr. Fellin was responsible for overseeing all Bioinformatics development and Information Technology systems at Illumigen Biosciences. In earlier successes, he was responsible for multiple commercial software programs with total revenues over 30 million in program management positions at 360 Powered Corporation, WRQ, and Attachmate corporation. His products have earned multiple user interface awards from national computing magazines. At The Boeing Company, he represented the company in briefings to US Air Force General Staff and was responsible for research and development aspects of the B-1B avionics program. He earned a B.S. in Electrical Engineering from the University of Michigan and Masters of Software Engineering from Seattle University.
Pauline Kenny, J.D.
Pauline Kenny heads all legal, corporate governance and regulatory compliance initiatives at Kineta and its corporate affiliates and subsidiaries. Ms. Kenny brings over 16 years of legal experience working both in-house and as outside counsel and is admitted to practice law in Washington.
Prior to joining Kineta’s legal team in 2012, Ms. Kenny practiced law at Beacon Law Advisors, PLLC where she represented a wide variety of emerging and established companies and advised clients in areas such as debt and equity financings, licensing matters, intellectual property protection, merger and acquisition transactions, employment issues, and service agreements. Ms. Kenny has also served as in-house counsel to Sproqit Technologies, Inc., a software applications company. Ms. Kenny earned a B.A. in Communications from the University of Washington and a J.D. from Seattle University.
Senior Vice President Corporate Development
Ken North heads corporate development and is responsible for generating financing for Kineta and its array of drug development programs. He strategically matches Kineta's short and long-term goals with those of investors. As a member of Kineta's executive team, Mr. North manages the finance department and also contributes to high level financial and strategic planning. He also ensures that investors are given high quality and frequent updates on Kineta's scientific and business developments.
Prior to joining Kineta in 2008, Mr. North spent nearly thirty years managing financial institutions. Most recently, he served as founding President and CEO at Seattle Bank and was instrumental in launching and licensing the bank at its inception and leading the bank to become the nation’s most profitable bank of its size in 2007. Before that, Mr. North held key leadership positions at Metropolitan Savings Bank and was responsible for generating and managing $350 million in deposits. He gives back generously to many important community organizations holding leadership roles and serving on boards. Mr. North currently serves as president of the Seattle Kiwanis Memorial Fund, providing funding and volunteer services to disadvantaged youth and fighting against human trafficking with the development of Redlight Traffic, a first in class app for citizens to report trafficking activity anonymously to authorities.
Eric Tarcha, Ph.D.
Vice President Translational Development
Dr. Eric Tarcha is a founding scientist at Kineta and heads translational development programs. This includes non-clinical and clinical activities to progress lead therapeutics through formal preclinical development and into first in man studies. He and his team are directly responsible for all in vitro and in vivo pharmacology studies including pharmacokinetic-pharmacodynamic characterization, toxicology, assay development, and clinical operations across all of Kineta’s development programs. Dr. Tarcha and his team are also responsible for CMC related activities including drug substance and product manufacturing, analytical assay development, formulations, and quality systems.
Dr. Tarcha received his B.S. and M.S. degrees in Medical Technology and Clinical Laboratory Sciences at Michigan State University and earned his PhD in Microbiology and Immunology from the Medical University of Ohio at Toledo. Prior to Kineta, he was a scientist at Illumigen Biosciences leading efforts in assay development, in vivo pharmacology and process development for a novel biologic antiviral therapy.